CIPO trademark

TYLTREEO

FiledCIPOWord markClass 5

"TYLTREEO" is a word mark owned by Pfizer Inc., filed at the CIPO on September 23, 2026. It is filed and waiting for examination and covers class 5 (Pharmaceuticals).

Get this data via the API

Data current as of October 1, 2026Official CIPO record

TYLTREEO

Word mark as filed with the CIPO

Status: Filed; Since September 23, 2026
Filed: September 23, 2026
Registered: Not yet
Expires: Not recorded
Application no.: 2502990
Registration no.: Not yet
Office: CIPO; Canadian Intellectual Property Office
Mark type: Word mark; 1 class

Ownership

Who owns TYLTREEO

The owner and representative on file with the office.

Owner

Pfizer Inc.

United States

Representative

Torys LLP

Goods and services

What the mark covers

The products and services TYLTREEO is filed for, grouped by Nice class.

05Class 5 · Pharmaceuticals
Antifungal pharmaceutical preparations; Antiviral pharmaceutical preparations; Anti-inflammatory pharmaceutical preparations; Pharmaceutical preparations for human use, namely, pharmaceutical antibodies for use as anti-infectives, and for use as anti-inflammatories; Pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely inflammatory bowel diseases, inflammatory connective tissue diseases; Pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; Pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries namely connective tissue diseases, bone diseases and osteoporosis; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of hematological diseases and disorders; Pharmaceutical preparations for the treatment of cardiovascular diseases; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for diagnosing and treating neurodegenerative diseases; Pharmaceutical preparations for the treatment of autonomic nerve disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; Pharmaceutical preparations for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment namely nausea and vomiting, hematologic depression, mucositis, cachexia, pain and bone pain, fatigue; Pharmaceutical preparations for treatment of autoimmune diseases and disorders; Pharmaceutical preparations for use in the treatment of immunological disorders; Pharmaceutical preparations for the treatment of dermatological diseases and disorders; Pharmaceutical preparations for the treatment of dermatological conditions being acne, rosacea, ichthyosis, vitiligo, urticaria and alopecia areata; Pharmaceutical preparations for the treatment of dermatitis, eczema, skin pigmentation diseases and psoriasis; Pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; Pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases and disorders; Pharmaceutical preparations for the treatment and management of vasomotor symptoms and symptoms associated with menopause Pharmaceutical preparations for the treatment of obesity; Pharmaceutical preparations for the treatment of migraine; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for use in gene therapy; Pharmaceutical preparations for the treatment of genetic disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; Pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; Pharmaceutical preparations for treating opioid overdoses; Human vaccine preparations

History

What has happened so far

Steps recorded by the CIPO, newest first.

September 23, 2026Formalized
September 23, 2026Created
September 23, 2026Filed

FAQ

About TYLTREEO

Who owns the trademark "TYLTREEO"?

The CIPO trademark "TYLTREEO" (application 2502990) is owned by Pfizer Inc.

What is the status of "TYLTREEO"?

Its status at the CIPO is: filed.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull TYLTREEO and marks like it into your own product with one request.

GET/v1/trademarks/{id}
The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/events
Every step in the office history
GET/v1/proceedings?trademark_id={id}
Oppositions and cancellations against the mark

Get API key View docs

GET /v1/trademarks/{id}

ID=tm_01a0f91b-014e-75fe-b778-d886b5317270
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"

Response

{
  "id": "tm_01a0f91b-014e-75fe-b778-d886b5317270",
  "object": "trademark",
  "mark_text": "TYLTREEO",
  "status": {
    "primary": "pending",
    "stage": "filed"
  },
  "office_code": "CA",
  "application_number": "2502990",
  "filing_date": "2026-09-23",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "Pfizer Inc.",
      "entity_id": null
    }
  ]
}